Cancer In Vitro Diagnostics (IVD) Market Report 2026

Cancer In Vitro Diagnostics (IVD) Market Overview

• Cancer In Vitro Diagnostics (IVD) market size has reached to $14.32 billion in 2025 • Expected to grow to $19.85 billion in 2030 at a compound annual growth rate (CAGR) of 6.7% • Growth Driver: Increasing Incidence Of Cancer Fueling The Growth Of The Market Due To Rising Aging Population • Market Trend: FDA Approval Marks A Breakthrough In Non-Invasive Cancer Screening • North America was the largest region in 2025 and Asia-Pacific is the fastest growing region.

What Is Covered Under Cancer In Vitro Diagnostics (IVD) Market?

Cancer in vitro diagnostics (IVD) refers to diagnostic tests performed outside the human body on samples such as blood, tissue, or other bodily fluids to detect, monitor, or manage cancer. These tests help in early detection, diagnosis, prognosis, and treatment selection for cancer patients by analyzing biomarkers, genetic mutations, and other indicators related to cancer. The main product types of cancer in vitro diagnostics (IVD) are reagents and kits, instruments, and software and services. Reagents and kits refer to ready-to-use chemicals and prepared testing materials used to detect cancer markers and analyze samples in cancer in vitro diagnostics (IVD) tests. It uses various other technologies such as clinical chemistry, immunochemistry or immunoassays, hematology, coagulation and hemostasis, microbiology, molecular diagnostics, and others. The various cancer type, including breast cancer, lung cancer, prostate cancer, and colorectal cancer and they cater to several end users, such as hospitals, laboratories, academics, point-of-care testing, patient self-testing, and others.

What Is The Cancer In Vitro Diagnostics (IVD) Market Growth Forecast?

The cancer in vitro diagnostics (ivd) market size is expected to see strong growth in the next few years. It will grow to $19.85 billion in 2030 at a compound annual growth rate (CAGR) of 6.7%. The growth in the forecast period can be attributed to increasing demand for personalized oncology diagnostics, rising investments in genomic sequencing, expansion of point-of-care cancer testing, growing integration of cloud-based diagnostic platforms, increasing focus on precision medicine. Major trends in the forecast period include increasing adoption of molecular and genomic cancer testing, rising use of companion diagnostics, growing integration of AI-driven data analysis, expansion of liquid biopsy applications, enhanced focus on early cancer detection.

Global Cancer In Vitro Diagnostics (IVD) Market Segmentation

1) By Product Type: Reagents And Kits, Instruments, Software And Services 2) By Technology: Clinical Chemistry, Immunochemistry Or Immunoassays, Hematology, Coagulation And Hemostasis, Cytogenetics Or Liquid Biopsy Technologies, Molecular Diagnostics, Other Technology 3) By Cancer Type: Breast Cancer, Lung Cancer, Prostate Cancer, Colorectal Cancer 4) By End-Users: Hospitals, Laboratories, Academics, Point-Of-Care Testing, Specialty Oncology Diagnostic Centers, Other End Users Subsegments: 1) By Reagents And Kits: PCR Reagents And Kits, NGS Reagents And Kits, Immunoassay Reagents And Kits, In Situ Hybridization (ISH) Reagents And Kits, Others 2) By Instruments: PCR Instruments, NGS Instruments, Immunoassay Analyzers, ISH Instruments, Others 3) By Software And Services: Data Analysis Software, Laboratory Information Management Systems, Cloud-Based Data Management, Instrument Integration Software, Support And Maintenance Services

What Is The Driver Of The Cancer In Vitro Diagnostics (IVD) Market?

The increasing incidence of cancer is expected to propel the growth of the cancer in vitro diagnostics (IVD) market going forward. Cancer refers to the uncontrolled growth and spread of abnormal cells in the body, which can invade nearby tissues and form tumors. The increasing incidence of cancer is due to the aging population, with longer life expectancy and reduced infectious disease mortality resulting in more elderly individuals who are at higher risk of developing cancer. Cancer in vitro diagnostics (IVD) helps in cancer by enabling early and accurate detection, monitoring, and management of the disease through laboratory tests performed on patient samples, allowing timely treatment decisions and improving patient outcomes. For instance, in January 2023, according to the American Cancer Society, a US-based professional organization dedicated to eliminating cancer, the society reported that 1,958,310 new cancer cases and 609,820 cancer deaths are projected to occur in 2023 in the United States. Therefore, the increasing incidence of cancer is driving the growth of the cancer in vitro diagnostics (IVD) industry.

Key Players In The Global Cancer In Vitro Diagnostics (IVD) Market

Major companies operating in the cancer in vitro diagnostics (ivd) market are F. Hoffmann-La Roche Ltd, Thermo Fisher Scientific Inc., Abbott Laboratories, Danaher Corporation, Siemens Healthineers AG, Hologic Inc., Illumina Inc., Sysmex Corporation, Exact Sciences Corporation, Bio-Rad Laboratories Inc., QIAGEN N.V., Autobio Diagnostics Co Ltd., Transasia Bio-Medicals Ltd., NanoString Technologies Inc., Genetron Holdings Limited, Cancer Diagnostics Inc., J. Mitra & Co. Pvt Ltd., Tulip Diagnostics Pvt Ltd., Guardant Health Inc., Agilent Technologies Inc., BGI Genomics

Global Cancer In Vitro Diagnostics (IVD) Market Trends and Insights

Major companies operating in the cancer in vitro diagnostics market are focusing on innovation in cancer screening, such as blood-based colorectal cancer (CRC) screening to provide convenient, non-invasive, and accurate early detection of colorectal cancer. Blood-based CRC screening refers to detecting cancer-associated molecular alterations, such as circulating tumor DNA (ctDNA), in a patient’s blood sample to identify colorectal cancer in average-risk individuals. For instance, in July 2024, Guardant Health, Inc., a U.S.-based precision oncology company, received U.S. Food and Drug Administration (FDA) approval for the Guardant Shield blood test as a primary colorectal cancer screening option. The test functions by analyzing a blood sample for specific ctDNA methylation patterns and other tumor-derived markers; unique features include noninvasive collection, high analytical accuracy, and integration with clinical workflows for primary screening; applications span colorectal cancer early detection in average-risk adults; benefits include improved patient adherence, earlier detection of malignancy, potential reduction in late-stage diagnoses, and eligibility for Medicare reimbursement, enabling broader population access to screening.

What Are Latest Mergers And Acquisitions In The Cancer In Vitro Diagnostics (IVD) Market?

In June 2025, QIAGEN N.V., a Netherlands-based life sciences and molecular diagnostics company, partnered with Gencurix Co., Ltd., to develop QIAcuity Digital PCR IVD assays. With this partnership, QIAGEN N.V. and Gencurix Co., Ltd. aim to enhance precision diagnostics by combining QIAGEN’s digital PCR technology with Gencurix’s biomarker discovery and assay development expertise, accelerating innovation in molecular testing and clinical applications. Gencurix Co., Ltd. is a South Korea-based biotechnology company that specializes in developing biomarker-based diagnostics and assay solutions for precision medicine.

Regional Outlook

North America was the largest region in the cancer in vitro diagnostics (IVD) market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in this market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in this market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

What Defines the Cancer In Vitro Diagnostics (IVD) Market?

The cancer in vitro diagnostics (IVD) market consists of revenues earned by entities by providing services such as cancer screening, early detection testing, diagnostic analysis, and personalized treatment guidance. The market value includes the value of related goods sold by the service provider or contained within the service offering. The cancer in vitro diagnostics (IVD) market also includes sales of reagents, assay kits, diagnostic instruments, molecular diagnostic platforms, and immunoassay systems. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What Key Data and Analysis Are Included in the Cancer In Vitro Diagnostics (IVD) Market Report 2026?

The cancer in vitro diagnostics (ivd) market research report is one of a series of new reports from The Business Research Company that provides market statistics, including industry global market size, regional shares, competitors with the market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the cancer in vitro diagnostics (ivd) industry. The market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.